Lisi L, Ciotti G M P, Braun D, Kalinin S, Currò D, Dello Russo C, Coli A, Mangiola A, Anile C, Feinstein D L, Navarra P
Institute of Pharmacology, Catholic University Medical School, L.go F. Vito 1, Rome, 00168, Italy.
Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL, USA.
Neurosci Lett. 2017 Apr 3;645:106-112. doi: 10.1016/j.neulet.2017.02.076. Epub 2017 Mar 2.
Microglia and macrophages appear to be the most common cells in the GBM microenvironment. In the present study we investigated the status of macrophages/microglia activation in surgical specimens from 41 patients diagnosed with grade IV GBM. For each patient we analyzed both the center of tumor and the parenchyma surrounding the tumor. The specimens were stained for: i) IBA1, a 17-kDa EF hand protein specifically expressed in microglia/macrophages ii) CD163, a cell surface antigen associated with M2 phenotype; iii) iNOS, taken as a functional marker of M1 phenotype, and iv) ARG-I, taken as a functional marker of M2 phenotype. Staining was scored in a double-blinded score on a scale from 0 to 5. Our results suggest that CD163 expression is higher within the tumor than in surrounding periphery in both male and female patients; while iNOS is higher within the tumor in males, no significant difference was found for ARG-1. In addition, analyzing the data in TGCA database, we found that CD163 expression was significantly and inversely correlated with mean survival times, with average survival times ranging from 448days in patients having low expression, to 319 in mid, and 353 in patients with high CD163 expressing tumors. In contrast, no significant association was found between survival time and ARG-1 or iNOS expression.
小胶质细胞和巨噬细胞似乎是胶质母细胞瘤微环境中最常见的细胞。在本研究中,我们调查了41例诊断为IV级胶质母细胞瘤患者手术标本中巨噬细胞/小胶质细胞的激活状态。对于每位患者,我们分析了肿瘤中心和肿瘤周围的实质组织。标本进行了如下染色:i)IBA1,一种在小胶质细胞/巨噬细胞中特异性表达的17 kDa EF手蛋白;ii)CD163,一种与M2表型相关的细胞表面抗原;iii)诱导型一氧化氮合酶(iNOS),作为M1表型的功能标志物;iv)精氨酸酶-I(ARG-I),作为M2表型的功能标志物。染色采用双盲评分,范围为0至5分。我们的结果表明,在男性和女性患者中,肿瘤内CD163的表达均高于周围组织;而男性患者肿瘤内iNOS表达较高,ARG-1未发现显著差异。此外,通过分析TGCA数据库中的数据,我们发现CD163表达与平均生存时间呈显著负相关,低表达患者的平均生存时间为448天,中等表达患者为319天,高表达患者为353天。相比之下,生存时间与ARG-1或iNOS表达之间未发现显著关联。